Mom's Belief Parent Targets 319 New Centres by FY29; Revenue More Than Doubles in FY26 but Profit Declines

The Rays of Belief IPO opened for subscription on Tuesday, September 1, 2026, giving investors an opportunity to participate in the public offering of the parent company of Mom's Belief, a specialised provider of intervention and therapy services for children with neurodevelopmental disorders.

The IPO will remain open until September 3, with the company offering shares in the price band of ₹227 to ₹239 per share.

The issue comprises an entirely fresh issue of 52.30 lakh equity shares, with no Offer for Sale component. At the upper end of the price band, the issue will raise approximately ₹125 crore.

The minimum application lot is 62 shares, translating into a minimum investment of ₹14,818 at the upper end of the price band. The shares are proposed to list on the BSE and NSE on September 8.

Rays of Belief IPO: Key Details

The post-issue implied market capitalisation is estimated at approximately ₹474 crore to ₹500 crore, depending on the final issue price.

What Does Rays of Belief Do?

Rays of Belief is a for-profit social enterprise operating under the Mom's Belief brand.

The company provides personalised intervention programmes and therapy services for children with neurodevelopmental disorders, including:

• Autism Spectrum Disorder

• Attention-Deficit/Hyperactivity Disorder

• Down Syndrome

• Cerebral Palsy

• Intellectual Disability

• Learning Disabilities

• Global Developmental Delays

The company started operations in 2018 and has built a network of centres across India.

As of March 31, 2026, Rays of Belief operated 136 centres across 57 cities and 20 states and Union Territories and had served more than 58,000 children since commencing operations.

A Specialised Healthcare Segment With Long-Term Growth Potential

The company's investment proposition is closely linked to the growth of India's neurodevelopmental-disorder intervention and behavioural-health market.

Analysts cited in the IPO coverage have pointed to rising awareness, increased diagnosis of developmental disorders and improving access to healthcare as factors supporting demand for specialised intervention services.

Master Capital Services estimated India's NDD market at around ₹52,623 million in CY25, with Autism Spectrum Disorder, ADHD and cerebral palsy accounting for around 73% of the market.

This creates a potentially attractive structural opportunity for organised providers such as Rays of Belief.

136 Centres Provide an Existing Operating Base

One of the company's major strengths is that it already has a sizeable physical network.

The company had 136 centres across 57 cities as of March 31, 2026.

It has also built a clinical workforce of more than 340 professionals and has served over 58,000 children since inception, according to analyst commentary.

This existing network gives Rays of Belief an established operating base from which it can expand further.

The company's focus on Tier-II and Tier-III cities could also provide an additional growth opportunity, given the relatively limited availability of structured developmental-care services in several smaller cities.

The Big Expansion Plan: 319 New Centres by FY29

The biggest growth trigger in the IPO is the company's ambitious expansion plan.

Rays of Belief intends to establish 319 additional centres between FY27 and FY29.

The planned additions include:

• 128 centres in Tier-I cities

• 121 centres in Tier-II cities

• 70 centres in Tier-III cities

If executed successfully, this would represent a significant expansion from the company's existing 136-centre network.

The plan could substantially increase the company's addressable market and revenue capacity.

However, it is also one of the biggest risks associated with the IPO.

Can the Company Execute Such Aggressive Expansion?

Rays of Belief is effectively planning to add more than twice its current number of centres within three years.

This is a significant operational challenge.

Opening a new centre is only the first step. The company also needs to recruit clinical professionals, build patient volumes, maintain service quality, manage occupancy and ensure that new centres become financially viable.

If the company expands faster than demand or talent availability, margins and cash flows could come under pressure.

Therefore, the success of the IPO story will depend heavily on how quickly new centres reach maturity and begin generating sustainable returns.

Where Will the IPO Money Be Used?

The fresh capital will primarily be deployed towards the company's expansion plans.

A significant portion is earmarked for establishing new centres, including expenditure on:

• Centre fit-outs

• Therapy-material inventory

• Technology hardware

The company has proposed an allocation of around ₹41.36 crore towards capital expenditure for new centres. Of this, approximately ₹34.99 crore is intended for centre fit-outs, ₹1.93 crore for therapy-material inventory and ₹4.44 crore for technology hardware.

Other proceeds are expected to support lease-related expenses, the US business, brand awareness and outreach programmes, along with other corporate purposes.

IPO Is Entirely a Fresh Issue

A positive feature of the IPO structure is that there is no Offer for Sale.

The entire 52.30 lakh-share offering is a fresh issue.

This means the capital raised will flow to the company for its stated objectives rather than being used by existing shareholders to sell their holdings.

For investors, this makes the deployment of IPO proceeds particularly important.

If the company can generate attractive returns on the new capital, earnings growth could accelerate.

If expansion consumes capital without generating sufficient revenue and cash flow, however, shareholder returns could remain under pressure.

Revenue More Than Doubles in FY26

Rays of Belief reported strong revenue growth in FY26.

Consolidated revenue from operations increased to ₹81.66 crore in FY26, compared with ₹36.42 crore in FY25.

This represents revenue growth of more than 120% year-on-year.

The sharp increase demonstrates that the business is capable of scaling its top line rapidly.

However, the company's profit trajectory tells a different story.

Profit Declines Despite Strong Revenue Growth

Profit for FY26 stood at approximately ₹4.96 crore, compared with ₹5.88 crore in FY25.

Therefore, while revenue more than doubled, profit actually declined.

This is an important warning signal for investors.

The numbers suggest that the company has not yet demonstrated that rapid revenue growth automatically translates into proportionate earnings growth.

Investors will need to monitor whether margins improve as the centre network scales.

Operating Margins Show Improvement, But Cash Flow Remains a Concern

FY26 operating profit was around ₹12.36 crore, with an operating margin of approximately 15.14%, according to available financial data.

However, operating cash flow remained negative at around ₹1.94 crore for FY26.

This is an important distinction.

The company has reported accounting profit, but its operating business did not generate positive cash flow during the year.

For a company preparing for aggressive expansion, cash generation will be an important monitorable.

Valuation: The Biggest Concern?

At the upper IPO price of ₹239, Rays of Belief is seeking a post-issue market capitalisation of around ₹500 crore.

Against FY26 profit of approximately ₹4.96 crore, this implies an indicative post-issue P/E multiple of roughly 101 times FY26 earnings.

This is a demanding valuation.

The calculation is based on the implied ₹500 crore post-issue market capitalisation and FY26 profit of ₹4.96 crore.

Such a valuation requires investors to assume that earnings will grow substantially over the coming years.

In other words, the IPO is not being priced as a low-growth healthcare company. The valuation already reflects significant expectations for future expansion.

Pre-IPO Placement Was Done at a Higher Price

Another interesting aspect is the company's pre-IPO fundraising.

Rays of Belief raised approximately ₹5.89 crore through pre-IPO private placements, with shares reportedly allotted at ₹284 and ₹290 per share.

The current IPO price band of ₹227–₹239 is therefore below those pre-IPO placement prices.

While this may appear positive from a pricing perspective, investors should not automatically interpret the earlier private-placement price as evidence that the IPO is undervalued.

The broader market environment, issue structure and investor demand can differ between private placements and public offerings.

Anchor Investors Put ₹50 Crore Into the IPO

Ahead of the public issue, Rays of Belief raised approximately ₹50 crore from anchor investors.

The company allotted around 20.92 lakh shares at ₹239 per share, the upper end of the IPO price band.

The anchor investors included Viney Growth Fund, LRSD Securities, Nova Global Opportunities Fund PCC – Touchstone, 31 Degrees North Fund-1 and Visionary Value Fund.

The anchor participation provides some evidence of institutional interest ahead of the public subscription period.

However, anchor participation should not be interpreted as a guarantee of post-listing performance.

Rays of Belief IPO GMP: Strong but Highly Unofficial

The grey market has shown a positive premium for Rays of Belief.

On September 1, reports indicated a GMP of around ₹48, which implied a potential listing price of approximately ₹287 against the upper issue price of ₹239, or around 20% above the issue price.

However, GMP numbers can change quickly during the IPO period.

The grey market is unofficial, and there is no guarantee that the actual listing price will match the implied GMP-based price.

Investors should therefore treat GMP as a sentiment indicator rather than a fundamental valuation tool.

Analysts Have a Mixed View

Analyst opinions on the IPO are not uniformly bullish.

The broad assessment is that Rays of Belief has a promising growth opportunity, but the stock carries meaningful risks relating to profitability, cash flow, valuation and execution.

Master Capital: Long-Term Growth Opportunity

Master Capital Services highlighted the favourable outlook for the NDD intervention market.

The brokerage pointed to the company's centre network, clinical workforce, multidisciplinary services and US expansion as potential growth drivers.

It believes Rays of Belief could benefit from increasing demand for specialised intervention and therapy services and views the IPO as a potential long-term investment opportunity.

Swastika Investmart: Neutral

Swastika Investmart has taken a more cautious position.

The brokerage highlighted the company's growth prospects but raised concerns over:

• Relatively short profitability history

• Negative operating cash flow in FY26

• Execution risk

• Aggressive expansion plans

• Difficulty in identifying directly comparable listed peers

Swastika's overall view is Neutral, arguing that the growth opportunity needs to be balanced against profitability, cash-flow and execution risks.

No Direct Listed Peer Makes Valuation Difficult

Another major issue for investors is the absence of a directly comparable listed company.

Rays of Belief operates in a specialised behavioural-health and neurodevelopmental intervention segment.

As a result, conventional peer comparison is difficult.

Investors cannot simply compare its P/E multiple with another listed company and determine whether the IPO is cheap or expensive.

Instead, the valuation has to be assessed against:

• Future revenue growth

• Centre expansion

• EBITDA margins

• Cash-flow generation

• Return on capital

• Centre-level profitability

• Patient volumes

• Scalability of the business model

US Expansion Adds Growth Potential

Rays of Belief has also expanded its presence in the United States.

Analysts believe this could provide an additional growth avenue in the behavioural-health market.

However, international operations also carry additional risks, including:

• Regulatory requirements

• Staffing costs

• Local competition

• Operating expenses

• Currency movements

• Market-entry costs

The US business therefore represents both a growth opportunity and an execution challenge.

Talent Availability Is a Key Risk

The company's business is people-intensive.

Clinical professionals are central to delivering therapy and intervention services.

As the company expands by hundreds of centres, recruitment and retention of qualified professionals could become a major challenge.

Higher employee costs could also impact margins if the company has to increase compensation to attract specialised talent.

Centre Economics Will Determine the Success of Expansion

For investors, one of the most important metrics to monitor after listing will be centre-level economics.

Opening 319 centres does not automatically create shareholder value.

The more important question is how quickly those centres reach break-even and generate sustainable operating profits.

Investors should therefore track:

• Revenue per centre

• Patient volumes per centre

• Centre utilisation

• Payback period

• Operating margin per centre

• New-centre break-even timeline

If the company can demonstrate attractive economics at the centre level, the expansion strategy could significantly improve earnings.

Key Growth Drivers

Several factors could support the company's long-term growth.

Rising Awareness

Greater awareness of developmental disorders could increase demand for diagnosis and intervention.

Increasing Diagnosis

Improved screening and diagnosis can expand the addressable patient population.

Tier-II and Tier-III Expansion

Smaller cities remain relatively underserved in specialised developmental care.

Large Centre Expansion Plan

The proposed 319 new centres could significantly increase capacity.

Technology Integration

Technology investments could improve operating efficiency and service delivery.

US Expansion

International operations could provide an additional revenue stream.

Major Risks for Investors

Aggressive Expansion

Adding 319 centres in three years is a significant execution challenge.

Profit Decline

Profit fell despite a more than doubling of revenue in FY26.

Negative Operating Cash Flow

Operating cash flow was negative in FY26, which raises questions about cash conversion.

High Valuation

At the upper band, the implied post-issue P/E is around 100 times FY26 profit.

Limited Peer Comparison

The lack of directly comparable listed companies makes valuation assessment difficult.

Talent Dependence

The business relies heavily on qualified clinical professionals.

International Risk

US operations could require significant investment before reaching scale.

Centre-Level Execution

The success of the expansion depends on how quickly new centres become profitable.

Rays of Belief IPO: Key Positives

The major positives include:

• Strong FY26 revenue growth

• 136 existing centres

• Presence across 57 cities

• Operations across 20 states and Union Territories

• More than 58,000 children served

• More than 340 clinical professionals

• Large NDD market opportunity

• Planned 319-centre expansion

• US expansion opportunity

• Entirely fresh issue

• ₹50 crore anchor investment

• Growing awareness of developmental disorders

Rays of Belief IPO: Key Negatives

The key concerns are:

• FY26 profit declined despite strong revenue growth

• Negative operating cash flow

• Aggressive expansion strategy

• High implied valuation

• Limited listed peers

• Dependence on clinical talent

• Execution risk

• Potential pressure on margins during expansion

• Uncertainty around the pace of US profitability

• GMP is unofficial and volatile

IPO Timeline

The key dates for investors are:

• IPO Opens: September 1, 2026

• IPO Closes: September 3, 2026

• Basis of Allotment: September 4, 2026

• Refund Initiation: September 7, 2026

• Share Credit: September 7, 2026

• Expected Listing: September 8, 2026

What Should Investors Track After Listing?

The post-listing performance should not be judged only by the initial share price.

Investors should track the company's quarterly performance with particular attention to:

Revenue growth: Can the company maintain its high growth rate?

Profit margins: Is operating leverage translating into higher profitability?

Operating cash flow: Can accounting profits convert into actual cash?

New centres: How many centres are being added and how quickly are they becoming profitable?

Centre utilisation: Are new facilities attracting sufficient patient volumes?

US operations: Is international expansion contributing meaningfully to earnings?

Return on capital: Are new investments generating adequate returns?

Debt and liquidity: Can the company fund its expansion without excessive financial pressure?

Rays of Belief IPO: Who Should Be Cautious?

Investors primarily looking for low valuations, established profitability and strong cash generation may find the IPO less attractive.

The issue is more dependent on future growth than on current earnings.

At the upper price band, the company is effectively asking investors to pay a significant premium for its future expansion opportunity.

Therefore, investors with a lower risk appetite should carefully consider the valuation and cash-flow profile before subscribing.

Who Could Consider the IPO?

Investors who have a long-term investment horizon and are comfortable with growth-stage healthcare businesses may find the company's business opportunity interesting.

However, even growth-oriented investors should be comfortable with the possibility that earnings may take time to catch up with the valuation.

The investment thesis depends heavily on successful execution of the company's expansion plans.

Rays of Belief IPO: Overall Assessment

Rays of Belief offers exposure to a specialised healthcare segment with potentially strong structural growth.

The company has already established a 136-centre network and served more than 58,000 children, providing a meaningful operating base.

Its plan to add 319 centres by FY29 could significantly increase its revenue opportunity.

The company's FY26 performance, however, highlights an important contradiction: revenue more than doubled, but profit declined and operating cash flow remained negative.

That makes the quality and sustainability of future growth particularly important.

At around ₹500 crore of post-issue market capitalisation at the upper band against FY26 profit of ₹4.96 crore, the valuation leaves limited room for execution disappointment.

Market Outlook

The Rays of Belief IPO presents a high-growth but high-expectation investment story.

The long-term opportunity in neurodevelopmental healthcare is attractive, while the company's established centre network, expanding clinical workforce and ambitious plans for 319 additional centres provide multiple growth triggers.

However, investors should not overlook the other side of the equation.

Revenue growth is currently much stronger than profit growth, operating cash flow was negative in FY26 and the post-issue valuation is demanding. The success of the IPO will therefore depend on whether Rays of Belief can convert its aggressive expansion into sustainable earnings and cash flows.

The current GMP indicates positive listing sentiment, but GMP remains unofficial and can change rapidly.

For investors evaluating the IPO beyond listing gains, the key question is not simply “How much can the stock list at?” but rather “Can the company grow earnings fast enough to justify the valuation?”

On the available information, the IPO offers a strong structural growth story but carries elevated valuation and execution risk. Investors considering the issue should therefore focus on long-term centre economics, profitability, cash-flow generation and capital efficiency rather than relying primarily on grey-market premiums.